RNAseq-Based Biomarkers Identify Targetable Biologic Drivers of Kidney Cancer
Abstract
Advanced kidney cancer has witnessed a great expansion of available therapies over the last two decades. Notably, drugs that inhibit tumor blood vessels (commonly called TKIs) and drugs that stimulate the immune system (commonly called IO) have become the mainstays of treatment. Currently, a combination of either two IO agents or one IO agent and one TKI are the standard initial treatment. At present, there are four such regimens to choose from. However, physicians have no tools to use to decide which particular treatment is best for an individual patient. This research proposal will directly benefit kidney cancer patients by giving providers a tool to help them select the regimen that will most benefit a particular patient. We will use advanced computing techniques to assign individual patients to biologic clusters by analyzing previously obtained tumor tissue. Then, depending on the type of cluster the patient s tumor is classified as, we will assign specific treatments. We think that individually tailored treatments will cause more patients tumors to shrink and be controlled for a longer period of time in the short term and in the long term result in curing more patients. This project is innovative in that for the first time we are using specific patient tumor information to guide treatment. If successful, this project will have implications for how we approach treatment not only in kidney cancer, but also more broadly for other cancers in Service Members, their families, Veterans, and the American public. This proposal directly addresses the KCRP 2021 Focus Areas of novel biomarkers and developing novel therapeutic approaches for kidney cancer.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Dec 28, 2022
- Source ID
- W81XWH2211008
Entities
People
- Brian I. Rini
Organizations
- United States Army
- Vanderbilt University